[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.249.135. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1993

Does Wavelength Matter When Photocoagulating Eyes With Macular Degeneration or Diabetic Retinopathy?

Author Affiliations

Baltimore, Md

Arch Ophthalmol. 1993;111(2):177-180. doi:10.1001/archopht.1993.01090020031017
Abstract

During the last two decades laser treatments have been shown to be effective in reducing the risk of visual loss in diabetic retinopathy,1-3 age-related macular degeneration (AMD),4-7 and branch retinal vein occlusions.8,9 While the number of successful clinical trials proliferated and the benefits of laser therapy in retinal and choroidal diseases became increasingly well established, there was a parallel explosion in technologic advances that simultaneously introduced a variety of newer lasers into the market. New instrumentation has yielded lasers that can produce wavelengths from blue-green to green to yellow and to red, each at the touch of a button. Each technological advance in the "rainbow" came with theoretical advantages, but will new technology improve efficacy of treatment? Only recently have clinical trials provided the opportunity to expand the evaluation of these various wavelengths from the theoretical realm to a more practical arena.

HISTORICAL PERSPECTIVES  One of

First Page Preview View Large
First page PDF preview
First page PDF preview
×